138 related articles for article (PubMed ID: 29024542)
21. Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin.
Washington C; Hou E; Hughes N; Berner B
Am J Health Syst Pharm; 2006 Apr; 63(7):653-6. PubMed ID: 16554289
[TBL] [Abstract][Full Text] [Related]
22. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
23. Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole.
de Kanter CT; Colbers AP; Blonk MI; Verweij-van Wissen CP; Schouwenberg BJ; Drenth JP; Burger DM
J Antimicrob Chemother; 2013 Jun; 68(6):1415-22. PubMed ID: 23429642
[TBL] [Abstract][Full Text] [Related]
24. Bioavailability of a controlled-release cyclobenzaprine tablet and influence of a high fat meal on bioavailability.
Gai MN; Costa E; Arancibia A
Int J Clin Pharmacol Ther; 2009 Apr; 47(4):269-74. PubMed ID: 19356393
[TBL] [Abstract][Full Text] [Related]
25. Relative bioavailability of diclofenac potassium from softgel capsule versus powder for oral solution and immediate-release tablet formulation.
Bende G; Biswal S; Bhad P; Chen Y; Salunke A; Winter S; Wagner R; Sunkara G
Clin Pharmacol Drug Dev; 2016 Jan; 5(1):76-82. PubMed ID: 27119581
[TBL] [Abstract][Full Text] [Related]
26. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
[TBL] [Abstract][Full Text] [Related]
27. Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects.
Lau YY; Gu W; Lin T; Song D; Yu R; Scott JW
J Clin Pharmacol; 2016 May; 56(5):559-66. PubMed ID: 26272586
[TBL] [Abstract][Full Text] [Related]
28. Effect of omeprazole on the pharmacokinetics of itraconazole.
Jaruratanasirikul S; Sriwiriyajan S
Eur J Clin Pharmacol; 1998 Apr; 54(2):159-61. PubMed ID: 9626921
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers.
Cullberg M; Arfvidsson C; Larsson B; Malmgren A; Mitchell P; Wählby Hamrén U; Wray H
Drugs R D; 2018 Jun; 18(2):149-159. PubMed ID: 29856004
[TBL] [Abstract][Full Text] [Related]
30. Relative bioavailability and pharmacokinetic study of omeprazole 20 mg enteric-coated tablet in healthy Bangladeshi volunteers.
Hasan A; Abul Kalam Azad M; Ullah MA; Mahbub Latif AH; Hasnat A
Int J Clin Pharmacol Ther; 2009 Mar; 47(3):215-21. PubMed ID: 19281731
[TBL] [Abstract][Full Text] [Related]
31. Effect of food on the bioavailability of palbociclib.
Ruiz-Garcia A; Plotka A; O'Gorman M; Wang DD
Cancer Chemother Pharmacol; 2017 Mar; 79(3):527-533. PubMed ID: 28204912
[TBL] [Abstract][Full Text] [Related]
32. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors.
Cox DS; Allred A; Zhou Y; Infante JR; Gordon MS; Bendell J; Jones S; Burris H; Orford K
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):287-94. PubMed ID: 27136909
[TBL] [Abstract][Full Text] [Related]
33. A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).
Infante JR; Ramanathan RK; George D; Tan E; Quinlan M; Liu A; Scott JW; Sharma S
Cancer Chemother Pharmacol; 2015 Apr; 75(4):729-37. PubMed ID: 25648347
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers.
Giri N; Lam LH; LaBadie RR; Krzyzaniak JF; Jiang H; Hee B; Liang Y; Shaik MN
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1249-1260. PubMed ID: 29086063
[TBL] [Abstract][Full Text] [Related]
35. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
Bramer SL; Forbes WP
Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
[TBL] [Abstract][Full Text] [Related]
36. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.
Winston A; Back D; Fletcher C; Robinson L; Unsworth J; Tolowinska I; Schutz M; Pozniak AL; Gazzard B; Boffito M
AIDS; 2006 Jun; 20(10):1401-6. PubMed ID: 16791014
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.
Sarantopoulos J; Goel S; Chung V; Munster P; Pant S; Patel MR; Infante J; Tawbi H; Becerra C; Bruce J; Kabbinavar F; Lockhart AC; Tan E; Yang S; Carlson G; Scott JW; Sharma S
Cancer Chemother Pharmacol; 2016 Nov; 78(5):921-927. PubMed ID: 27681579
[TBL] [Abstract][Full Text] [Related]
38. Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients.
Mahadevan D; Mita M; Richards D; McClay E; Heist RS; Kumar A; Sundararajan S; Naing A
Cancer Chemother Pharmacol; 2017 Apr; 79(4):681-688. PubMed ID: 28289865
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects.
Xu H; O'Gorman M; Boutros T; Brega N; Kantaridis C; Tan W; Bello A
J Clin Pharmacol; 2015 Jan; 55(1):104-13. PubMed ID: 24990113
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
